| Index | S&P 500, NDX, DJIA | P/E | 27.30 | EPS (ttm) | 16.09 | Insider Own | 0.23% | Shs Outstand | 540.63M | Perf Week | 1.57% |
| Market Cap | 237.48B | Forward P/E | 17.94 | EPS next Y | 24.49 | Insider Trans | -0.58% | Shs Float | 539.16M | Perf Month | 8.18% |
| Enterprise Value | 280.79B | PEG | 4.27 | EPS next Q | - | Inst Own | 67.32% | Short Float | 2.60% | Perf Quarter | 16.74% |
| Income | 8.74B | P/S | 6.23 | EPS this Y | 8.12% | Inst Trans | 0.00% | Short Ratio | 5.19 | Perf Half Y | 27.49% |
| Sales | 38.13B | P/B | 20.32 | EPS next Y | 6.26% | ROA | 9.14% | Short Interest | 14.03M | Perf YTD | 34.20% |
| Book/sh | 21.62 | P/C | 16.98 | EPS next 5Y | 6.39% | ROE | 89.32% | 52W High | 450.99 -2.60% | Perf Year | 48.41% |
| Cash/sh | 25.88 | P/FCF | 23.34 | EPS past 3/5Y | 5.52% 2.94% | ROIC | 14.22% | 52W Low | 288.00 52.52% | Perf 3Y | 54.90% |
| Dividend Est. | 10.08 (2.29%) | EV/EBITDA | 15.93 | Sales past 3/5Y | 11.76% 7.64% | Gross Margin | 72.65% | Volatility | 2.28% 2.35% | Perf 5Y | 111.35% |
| Dividend TTM | 9.94 (2.26%) | EV/Sales | 7.37 | EPS Y/Y TTM | 112.83% | Oper. Margin | 33.18% | ATR (14) | 10.59 | Perf 10Y | 167.37% |
| Dividend Ex-Date | Aug 21, 2026 | Quick Ratio | 1.13 | Sales Y/Y TTM | 14.06% | Profit Margin | 22.93% | RSI (14) | 60.82 | Recom | 2.54 |
| Dividend Gr. 3/5Y | 7.05% 8.27% | Current Ratio | 1.37 | EPS Q/Q | 4.49% | SMA20 | 4.26% | Beta | 0.44 | Target Price | 403.79 |
| Payout | 60.45% | Debt/Eq | 6.31 | Sales Q/Q | 9.68% | SMA50 | 5.27% | Rel Volume | 0.60 | Prev Close | 447.28 |
| Employees | 31,500 | LT Debt/Eq | 5.78 | Earnings | Nov 03 | SMA200 | 18.21% | Avg Volume | 2.81M | Price | 439.26 |
| IPO Date | Jun 17, 1983 | Option/Short | Yes / Yes | EPS/Sales Surpr. | 11.97% 6.66% | Net Debt/EBITDA | 2.46 | Volume | 1,681,579 | Change | -1.79% |
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Oct-23-26 | Reiterated | Oppenheimer | Outperform | $450 → $480 |
| Oct-21-26 | Reiterated | Barclays | Equal Weight | $380 → $400 |
| Oct-13-26 | Reiterated | Guggenheim | Neutral | $388 → $378 |
| Oct-12-26 | Reiterated | Wells Fargo | Equal Weight | $435 → $430 |
| Oct-12-26 | Reiterated | BMO Capital | Market Perform | $450 → $415 |
| Oct-08-26 | Reiterated | RBC Capital | Outperform | $400 → $430 |
| Oct-08-26 | Reiterated | Cantor Fitzgerald | Neutral | $400 → $440 |
| Oct-07-26 | Reiterated | Truist Securities | Hold | $325 → $380 |
| Sep-23-26 | Reiterated | Jefferies | Buy | $350 → $410 |
| Sep-17-26 | Reiterated | UBS | Buy | $420 → $430 |
Amgen Inc., established in 1980 and headquartered in Thousand Oaks, California, is a global biotechnology leader focused on discovering, developing, manufacturing, and delivering groundbreaking human medicines. The company's scientific endeavors span several critical therapeutic categories, including inflammatory conditions, oncology and hematology, bone health, cardiovascular diseases, nephrology, and neuroscience. Its extensive portfolio features a range of significant pharmaceutical products. Notable examples include Enbrel, prescribed for conditions like plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta, which helps cancer patients by reducing the risk of infection linked to a low white blood cell count; Prolia, utilized in postmenopausal women to combat osteoporosis; and Xgeva, designed to prevent skeletal-related complications. Otezla offers relief for adult patients suffering from plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease. Aranesp addresses anemia and low red blood cell counts, while KYPROLIS is employed to treat patients with relapsed or refractory multiple myeloma. Furthermore, Repatha plays a vital role in lowering the incidence of major cardiovascular events such as myocardial infarction, stroke, and coronary revascularization. Amgen's comprehensive product lineup also encompasses Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. The company distributes its therapies worldwide, primarily serving healthcare providers, including physicians and their clinics, dialysis centers, hospitals, and pharmacies. Distribution is facilitated through pharmaceutical wholesale distributors, complemented by direct-to-consumer channels. Amgen actively engages in strategic collaborations. It has partnered with entities such as Novartis Pharma AG, UCB, Bayer HealthCare LLC, BeiGene, Ltd., Eli Lilly and Company, Datos Health, and Verastem, Inc., to jointly assess VS-6766 when combined with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. Another key alliance involves Kyowa Kirin Co., Ltd., for the co-development and commercialization of KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody targeting atopic dermatitis and other autoimmune conditions. Additionally, Amgen maintains research and development partnerships with Neumora Therapeutics, Inc. and Plexium, Inc.
Per-holder 13F data hasn't been ingested for this ticker yet.
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 38,125 | 36,741 | 33,424 | — | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 10,427 | 10,729 | 12,858 | — | — | — | — | — | — | |
| Gross Profit | 27,698 | 26,012 | 20,566 | — | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 7,004 | 7,050 | 7,096 | — | — | — | — | — | — | |
| Research and Development | 7,638 | 6,974 | 5,964 | — | — | — | — | — | — | |
| Other Operating Expense | 408 | 1,312 | 248 | — | — | — | — | — | — | |
| Operating Income | 12,648 | 10,676 | 7,258 | — | — | — | — | — | — | |
| Interest Expense | 2,668 | 2,755 | 3,155 | — | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | 307 | 1,055 | 506 | — | — | — | — | — | — | |
| Net Income Before Taxes | 10,287 | 8,976 | 4,609 | — | — | — | — | — | — | |
| Income Taxes | 1,544 | 1,265 | 519 | — | — | — | — | — | — | |
| Consolidated Net Income | 8,743 | 7,711 | 4,090 | — | — | — | — | — | — | |
| Net Income From Continuing Operations | 8,743 | 7,711 | 4,090 | — | — | — | — | — | — | |
| Net Income | 8,743 | 7,711 | 4,090 | — | — | — | — | — | — | |
| EPS (Recurring) | 16.22 | 14.33 | 7.62 | — | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | 16.22 | 14.33 | 7.62 | — | — | — | — | — | — | |
| EPS (Diluted) | 16.09 | 14.23 | 7.56 | — | — | — | — | — | — | |
| EBITDA | 17,622 | 16,898 | 13,356 | — | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | 27.30 | 23.00 | 34.48 | — | — | — | — | — | — | |
| Price To Sales Ratio | 6.22 | 4.79 | 4.22 | — | — | — | — | — | — | |
| Gross Margin | 72.65 | 70.80 | 61.53 | — | — | — | — | — | — | |
| Operating Margin | 33.18 | 29.06 | 21.71 | — | — | — | — | — | — | |
| Net Margin | 22.93 | 20.99 | 12.24 | — | — | — | — | — | — | |
| Shares Outstanding | 540 | 538 | 541 | — | — | — | — | — | — | |
| Market Capitalization | 237,200 | 176,093 | 141,006 | — | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Khosla Rachna | SVP, Business Development | Aug 13 '26 | Option Exercise | 162.60 | 1,252 | 203,575 | 7,656 | Aug 13 |
| Khosla Rachna | SVP, Business Development | Aug 13 '26 | Sale | 416.43 | 1,252 | 521,365 | 6,404 | Aug 13 |
| Khosla Rachna | SVP, Business Development | Aug 11 '26 | Sale | 412.57 | 2,000 | 825,134 | 6,404 | Aug 13 |
| Grygiel Nancy A. | SVP & CCO | Aug 06 '26 | Option Exercise | 177.41 | 2,970 | 526,906 | 9,310 | Aug 07 |
| Grygiel Nancy A. | SVP & CCO | Aug 06 '26 | Sale | 402.16 | 1,000 | 402,160 | 7,340 | Aug 07 |
| Miller Derek | SVP, Human Resources | Aug 06 '26 | Option Exercise | 169.56 | 3,890 | 659,574 | 14,531 | Aug 07 |
| Miller Derek | SVP, Human Resources | Aug 06 '26 | Sale | 402.54 | 1,821 | 733,033 | 12,462 | Aug 07 |
| Grygiel Nancy A. | SVP & CCO | May 04 '26 | Sale | 323.73 | 1,237 | 400,451 | 7,009 | May 05 |
| Bradway Robert A | Chairman, CEO and President | Mar 04 '26 | Option Exercise | 156.35 | 119,782 | 18,727,916 | 576,928 | Mar 06 |
| Santos Esteban | EVP, Operations | Feb 26 '26 | Option Exercise | 169.19 | 54,792 | 9,270,144 | 107,119 | Mar 02 |
| Santos Esteban | EVP, Operations | Feb 26 '26 | Sale | 379.12 | 24,291 | 9,209,138 | 76,618 | Mar 02 |
| Busch Matthew C. | VP, Finance & CAO | Feb 19 '26 | Sale | 375.79 | 1,000 | 375,790 | 3,423 | Feb 20 |
| Grygiel Nancy A. | SVP & CCO | Nov 20 '25 | Option Exercise | 169.70 | 3,139 | 532,691 | 8,864 | Nov 21 |
| Grygiel Nancy A. | SVP & CCO | Nov 20 '25 | Sale | 337.26 | 1,639 | 552,773 | 7,225 | Nov 21 |
| Khosla Rachna | SVP, Business Development | Nov 12 '25 | Sale | 336.24 | 890 | 299,256 | 7,082 | Nov 13 |